申请人:Neurogen Corporation
公开号:US20020143019A1
公开(公告)日:2002-10-03
A compound of formula (IA) or the pharmaceutically acceptable acid addition salts thereof wherein: R
1
, R
2
, R
3
, R
4
and R
5
are the same or different and represent hydrogen, halogen, C
1
-C
6
alkyl, C
1
-C
4
-alkoxy, C
1
-C
4
akylthio, hydroxy,
1
amino, mono(C
1
-C
6
) alkylamino, di(C
1
-C
6
)alkylamino, cyano, nitro, trifluoromethyl or trifluoromethoxy; R
6
is hydrogen or C
1
-C
6
alkyl; W is nitrogen, COH, or CH; Y and Z independently represent nitrogen or CH; and A represents an alkylene group of from 2-5 carbon atoms optionally substituted with one or more alkyl groups having from one to four carbon atoms. The compounds of the invention demonstrate high affinity and selectivity in binding to the D
4
receptor subtype.
式 (IA) 的化合物或其药学上可接受的酸加成盐 其中R
1
, R
2
, R
3
, R
4
和 R
5
相同或不同,代表氢、卤素、C
1
-C
6
烷基、C
1
-C
4
-烷氧基、C
1
-C
4
烷硫基、羟基
1
氨基,单(C
1
-C
6
烷基氨基,二(C
1
-C
6
)烷基氨基、氰基、硝基、三氟甲基或三氟甲氧基;R
6
是氢或 C
1
-C
6
烷基;W 是氮、COH 或 CH;Y 和 Z 独立地代表氮或 CH;A 代表 2-5 个碳原子的亚烷基,可选地被一个或多个具有 1-4 个碳原子的烷基取代。本发明的化合物在与 D
4
受体亚型的高亲和性和选择性。